Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday
Intellia Therapeutics (NTLA) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th. Analysts are forecasting a loss of ($0.99) per share on revenue of approximately $12.17 million. Company insiders, including CEO John M. Leonard and EVP Birgit C. Schultes, have recently sold shares, with institutional investors holding a significant portion of the stock.
Intellia Therapeutics to Host Conference Call on February 26, 2026, to Discuss Q4 and Full-Year 2025 Financial Results
Intellia Therapeutics will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and business updates. The company, a leader in CRISPR-based gene editing, aims to revolutionize medicine for unmet medical needs. A webcast and phone access details are provided, with a replay available for 90 days.
to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced it will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide business updates. Interested parties can join via webcast or teleconference, with a replay available online for approximately 90 days. The company, a clinical-stage gene editing firm, aims to revolutionize medicine with CRISPR-based therapies for unmet medical needs.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics has announced it will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results. The clinical-stage gene editing company will also provide business updates regarding its CRISPR-based therapy platform.
Intellia earnings in focus after FDA lifts CRISPR therapy hold
Intellia Therapeutics Inc. is set to report its fourth-quarter results, with investors keenly focused on management's discussion regarding the FDA's recent lifting of a clinical hold on its lead gene-editing therapy, nexiguran ziclumeran. Analysts anticipate a loss of 96 cents per share on revenue of $12.08 million, and the company will need to reassure investors about its cash runway and the broader pipeline. The focus will be on updates related to the MAGNITUDE-2 trial and engagement with the FDA on the related ATTR-CM trial, as well as the company's ability to demonstrate that safety issues are manageable risks.
Intellia earnings in focus after FDA lifts CRISPR therapy hold
Intellia Therapeutics Inc. is set to release its fourth-quarter earnings, with investors keenly focused on management's outlook following the FDA's decision to lift the clinical hold on its lead gene-editing therapy, nexiguran ziclumeran. Analysts expect a loss of 96 cents per share on $12.08 million in revenue, and attention will be on updates regarding trial enrollment timelines, liver safety monitoring, and the ongoing hold on a related trial, as well as the company's cash runway. The report will be crucial in determining whether the safety incidents are perceived as manageable risks or fundamental flaws in Intellia's CRISPR platform.
Clinical Hold Lifted On MAGNITUDE-2 Reshapes Intellia Gene Editing Risk Profile
Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing the trial to resume with updated protocols, including a larger patient enrollment target and additional risk mitigation. This development could significantly impact Intellia's clinical pipeline risk, especially for its in vivo CRISPR treatments, and may influence future pricing discussions and partnership interest. Investors will now focus on safety signals and trial execution as the program continues.
Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors
Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, enabling the gene editing trial to resume with expanded enrollment and updated safety protocols. This decision removes a significant regulatory hurdle for Intellia, a clinical-stage gene editing company whose stock has seen mixed performance, with a 32.7% gain year-to-date but a substantial decline over three and five years. While the lift is positive, investors should monitor trial execution, safety updates, and the company's path to profitability, as Intellia is currently unprofitable and faces competition in the gene editing space.
Did FDA’s MAGNITUDE-2 Clearance and Safety Focus Just Reframe Intellia Therapeutics' (NTLA) Risk Profile?
The FDA lifting the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing expanded enrollment with enhanced safety monitoring, is seen as reinforcing confidence in the company's gene-editing platform. This decision clears a near-term obstacle for its ATTRv-PN program and aligns with a cautious clinical framework for its broader ATTR amyloidosis strategy. While promising for potential regulatory submissions, investors are advised to remain aware of heightened regulatory and safety scrutiny regarding serious liver events in gene-editing therapies.
H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted
H.C. Wainwright has raised its price target for Intellia Therapeutics (NTLA) to $25 from $15 and reiterated a Buy rating. This upgrade follows the lifting of a clinical hold on the company's MAGNITUDE-2 study. The revised protocol for the study now targets approximately 60 patients, an increase from 50, to mitigate risks and improve data understanding.
H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted
H.C. Wainwright has reiterated a Buy rating on Intellia Therapeutics, Inc. (NTLA) and raised its price target to $25 from $15. This follows the lifting of a clinical hold on the company's MAGNITUDE-2 study, with an updated protocol targeting around 60 patients and prioritizing risk mitigation. The analyst highlighted the rarity of safety incidents that led to the hold, noting two liver incidents in approximately 450 treated patients.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Intellia Therapeutics (Nasdaq: NTLA) announced it awarded inducement grants to six new employees on February 1, 2026, under its 2024 Inducement Plan. These grants, totaling 30,600 shares of common stock in time-based restricted stock units, were a material inducement to employment and will vest annually over three years. The awards were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Intellia Therapeutics, Inc. announced inducement grants to six new employees on February 1, 2026, under its 2024 Inducement Plan. These grants comprised restricted stock units for 30,600 shares, vesting annually over three years, as a material inducement for employment. The awards were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial
Intellia Therapeutics (NTLA) saw its shares rise significantly after the FDA lifted a clinical hold on its MAGNITUDE-2 Phase 3 trial. While a strong "undervalued" narrative suggests a fair value of $173.99 based on aggressive future growth assumptions, the company is currently loss-making with a high price-to-sales ratio compared to industry averages. This creates a debate on whether the current valuation reflects an early opportunity or leaves little room for error if future execution falters.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts
Intellia Therapeutics (NASDAQ:NTLA) has received a consensus "Hold" rating from twenty-one research firms, with an average 12-month price target of $18.00. Several analysts have recently cut their price targets for the gene-editing company. Insiders, including CEO John M. Leonard, have sold shares, reducing insider ownership, while institutional investors hold a significant portion of the stock.
A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial
Intellia Therapeutics (NTLA) is back in focus following the FDA's removal of a clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran, prompting a significant increase in its share price. While the stock has seen recent gains and is considered "92.9% Undervalued" by a popular narrative that projects a fair value of $173.99, other analyses highlight a steep price-to-sales ratio, suggesting potential overvaluation or high expectations. Investors are now evaluating whether the FDA news creates a new entry point that justifies future growth assumptions given the company is still loss-making.
Intellia Therapeutics (NTLA) Is Down 6.6% After FDA Lifts Hold On Key ATTRv-PN Trial – Has The Bull Case Changed?
Intellia Therapeutics saw its stock drop 6.6% despite the FDA lifting the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z), intended for ATTRv-PN patients. This decision allows the trial to resume enrollment, presenting a key clinical catalyst, although the ATTR-CM MAGNITUDE trial remains on hold due to liver safety concerns. The company's investment narrative remains heavily reliant on the success of its gene-editing therapies, with significant investor focus on clinical execution and regulatory confidence given ongoing losses and a volatile stock price.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics announced that on February 1, 2026, it awarded inducement grants to six new employees under its 2024 Inducement Plan. These grants consisted of restricted stock units for an aggregate of 30,600 shares, vesting annually over three years, and were approved by the compensation committee as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics announced that on February 1, 2026, it awarded inducement grants to six new employees, consisting of restricted stock units for 30,600 shares of common stock. These grants were made under Intellia's 2024 Inducement Plan as a material inducement to employment and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest annually over three years, contingent on continued service.
Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in Intellia Therapeutics (NTLA) by 68% in Q3, now owning 494,468 shares valued at $8.54 million. Despite the company posting a smaller-than-expected Q3 loss and a 51.6% YoY revenue increase to $13.78 million, it remains unprofitable with a negative net margin. The stock, currently trading down 10.3%, has a "Hold" rating from analysts with an average price target of $18.00.
Intellia Therapeutics Receives Key Regulatory Clearance for Clinical Trial
Intellia Therapeutics has received crucial regulatory clearance from the U.S. FDA to lift a clinical hold on its MAGNITUDE-2 Phase 3 study for NTLA-2001 (Nex-z), a CRISPR-based therapeutic for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This follows a previous setback due to a serious adverse event in a related trial. The company has implemented a revised protocol with enhanced patient monitoring and an increased enrollment target, though the original MAGNITUDE trial for ATTR-CM remains on hold.
Intellia Therapeutics (NTLA) Price Target Increased by 35.10% to 23.94
The average one-year price target for Intellia Therapeutics (NTLA) has been raised by 35.10% to $23.94 per share from $17.72. This new target represents an 83.47% increase from the last closing price of $13.05. Institutional ownership in NTLA has also increased, with total shares owned by institutions rising by 5.02% over the last three months, indicating a bullish outlook.
FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang
The FDA has lifted the clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial for Nexiguran Ziclumeran (Nex-Z), treating hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This decision allows the crucial gene editing program to proceed after a safety-related pause, removing a significant regulatory concern for investors. Intellia Therapeutics, which is currently loss-making, will continue with the trial under agreed study modifications and enhanced safety monitoring.
FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang
The FDA has lifted a clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial of Nexiguran Ziclumeran (Nex-Z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), allowing the trial to resume with modified study protocols and enhanced safety monitoring. This decision removes a significant regulatory overhang for Intellia Therapeutics (NasdaqGM:NTLA), enabling a key gene editing program to advance. The company, currently trading at US$13.05, is developing CRISPR-based therapies and, despite being loss-making, shows strong recent momentum.
FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story
The FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy, allowing the company to resume late-stage development of nexiguran ziclumeran. This decision addresses previous safety concerns and is expected to refocus Intellia's value story, although a separate hold on the cardiomyopathy study remains. The market will now focus on the trial's progression and future regulatory updates, as Intellia's stock has seen recent gains despite longer-term declines.
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal
Baird has updated its financial model for Intellia Therapeutics, Inc. (NTLA), raising its price target to $7 and maintaining a Neutral rating after the FDA lifted a clinical hold on the Nex-z hATTR-PN trial. H.C. Wainwright also increased its price target to $25 and maintained a Buy rating, citing manageability of Nex-Z's risks and increasing the probability of approval. Intellia Therapeutics is a clinical-stage biotechnology company focused on CRISPR-based gene editing therapies.
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal
Baird has updated its financial model for Intellia Therapeutics (NTLA) and raised its price target to $7 from $4, maintaining a Neutral rating, after the FDA lifted the clinical hold on the Nex-z hATTR-PN trial. Similarly, H.C. Wainwright analyst Mitchell Kapoor also increased NTLA's price target to $25 from $15 with a Buy rating, citing manageable risks for Nex-Z and increasing its probability of approval to 35%. Intellia Therapeutics is a clinical-stage biotechnology company developing CRISPR-based gene editing therapies for genetic diseases, though the article suggests other AI stocks may offer greater upside potential.
Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial
Intellia Therapeutics (NTLA) saw its shares drop 12.6% despite the FDA lifting the clinical hold on its MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis. The decision allows patient enrollment to resume with enhanced liver safety monitoring, marking a significant regulatory step for its CRISPR-based therapy. However, the MAGNITUDE cardiomyopathy trial remains on hold, and investors are weighing renewed trial progress against ongoing clinical, regulatory, and financing risks.
Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views
Eleven analysts have provided varied ratings for Intellia Therapeutics (NASDAQ: NTLA), with an average price target of $14.18, representing a 31.6% decrease from the previous average. Despite some decreases in price targets, the company shows strong financial metrics such as 51.27% revenue growth and above-average net margin, ROE, and ROA, alongside a sound debt-to-equity ratio. Intellia Therapeutics specializes in CRISPR/Cas9-based gene-editing therapies for genetically defined diseases and has collaborations with Regeneron and Novartis.
Intellia Therapeutics to resume dosing of gene therapy in Phase III trial
Intellia Therapeutics has received FDA approval to resume patient enrollment and dosing in its MAGNITUDE-2 Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), after a clinical hold was lifted. The hold was initially placed following the death of a patient in a related trial, MAGNITUDE, which remains on hold. Intellia's stock price increased following the announcement, and the company has agreed to modifications including enhanced safety monitoring and increased target enrollment for MAGNITUDE-2.
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
Intellia Therapeutics (NTLA) shares surged 6.3% after the FDA lifted a clinical hold on its MAGNITUDE-2 study for nexiguran ziclumeran, leading to increased investor confidence. The company expects to post a quarterly loss of $0.99 per share and revenues of $11.85 million. Despite the recent rally, the stock carries a Zacks Rank #3 (Hold), with future gains dependent on trends in earnings estimate revisions.
FDA lets Intellia resume MAGNITUDE-2 Phase 3 trial for ATTRv-PN
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The company plans to resume patient enrollment and dosing, has aligned with the FDA on enhanced liver safety monitoring, and increased the target enrollment from approximately 50 to 60 patients. Engagement with the FDA is ongoing for the related MAGNITUDE Phase 3 trial in ATTR-CM, which remains under clinical hold due to previous Grade 4 liver transaminases and increased bilirubin observations.
Intellia gets FDA nod to resume one gene therapy trial after safety pause
Intellia Therapeutics announced that the FDA has lifted a clinical hold on one of its late-stage gene therapy trials for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), allowing the company to resume patient enrollment. Shares of Intellia rose 10% on the news. A separate trial for ATTR cardiomyopathy (ATTR-CM) using the same therapy remains on hold following a patient's death due to severe liver-related side effects, and Intellia is working with the FDA on a path forward for that program.
FDA lifts hold on an Intellia CRISPR drug trial
The FDA has lifted a clinical hold on one of Intellia Therapeutics' Phase 3 trials for its CRISPR-based treatment, nexiguran ziclumeran (nex-z), for transthyretin amyloidosis. This comes after a serious liver toxicity event, including a participant's death, caused regulators to pause two trials last October. The company will implement new risk mitigation measures for the "MAGNITUDE-2" trial, which targets the nerve-affecting form of the disease, but the hold on the "MAGNITUDE" trial for cardiomyopathy patients remains.
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
The FDA has lifted a clinical hold on one of Intellia Therapeutics' gene editing programs, MAGNITUDE-2, for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This decision allowed Intellia's shares to rise by 10% and enables the company to resume patient enrollment for the Phase III trial. The hold was initially placed in October 2025 after a patient death in a related trial, though a hold remains on MAGNITUDE, the sister trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Trial
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for ATTRv-PN patients. The company has agreed to enhanced safety monitoring measures and plans to promptly resume patient enrollment and dosing, while also increasing the trial's enrollment target from 50 to 60 patients. Discussions with the FDA are ongoing for the MAGNITUDE trial for ATTR-CM.
FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial
The FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran in patients with ATTRv-PN, which was previously on hold due to a patient death from severe liver toxicity. Intellia plans to resume enrollment and dosing after protocol modifications and enhanced safety monitoring. However, the separate MAGNITUDE Phase 3 trial for ATTR-CM remains on clinical hold, leading to ongoing regulatory uncertainty for a key part of the program.
After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia's CRISPR therapy
The FDA has lifted a clinical hold on one of Intellia Therapeutics' CRISPR therapy trials, allowing a phase 3 study for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) to resume. This decision follows a patient death in a related study for transthyretin amyloid cardiomyopathy (ATTR-CM), which had led to a voluntary pause and subsequent regulatory hold. Intellia's stock saw a significant increase, and the company plans to implement new risk-mitigation procedures to prevent adverse events.
Intellia Therapeutics: Investors Await Regulatory Clarity
Intellia Therapeutics' stock performance is currently dependent on upcoming regulatory decisions concerning its clinical trials. While a clinical hold has been placed on its ATTR amyloidosis treatment (Nexiguran Ziclumeran) by the FDA, the company's hereditary angioedema (HAE) candidate (Lonvoguran Ziclumeran) is on track for a U.S. regulatory submission in late 2026. Investors are looking for clarity on the ATTR program's resumption before fully focusing on the HAE drug application.
Precision Trading with Intellia Therapeutics Inc. (NTLA) Risk Zones
This article provides a detailed analysis of Intellia Therapeutics Inc. (NTLA), highlighting strong sentiment across all horizons that supports an overweight bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels, and an exceptional 140.3:1 risk-reward setup targeting a significant gain.
A Look At Intellia Therapeutics (NTLA) Valuation After Safety Concerns And HAE Market Uncertainty
This article analyzes Intellia Therapeutics (NTLA) valuation amidst recent safety concerns and regulatory pauses in its transthyretin amyloidosis program, coupled with uncertainties around its hereditary angioedema (HAE) therapy. While a dominant narrative suggests the stock is 91.6% undervalued based on strong Phase 2 HAE data and future sales projections, a contrasting view highlights a high price-to-sales ratio compared to peers. The piece encourages investors to consider both clinical risks and potential rewards against market expectations.
Is ARK’s Buying Spree Reshaping Intellia Therapeutics’ (NTLA) Risk‑Reward Story Amid Clinical Uncertainty?
ARK Invest's recent three-day buying streak in Intellia Therapeutics (NTLA) has reignited interest in the stock, despite ongoing clinical holds for its ATTR program and mixed analyst ratings. This institutional confidence, coupled with the inherent uncertainties of CRISPR-based therapies and unresolved safety concerns, creates a complex risk-reward profile. The article emphasizes that while ARK's buying highlights investor willingness to brave volatility, it doesn't fundamentally alter the existing clinical and commercial challenges for Intellia.
Intellia Therapeutics Shares Rally on Renewed Clinical Confidence
Intellia Therapeutics saw a significant surge in its share price, gaining 14.4% and closing at $15.90, primarily due to increased institutional investment from ARK Invest and clarification on previous clinical hold concerns. CEO John Leonard confirmed that a patient fatality in the nex-z program was not due to liver toxicity from the CRISPR therapy, easing investor fears and suggesting a potential lifting of the FDA hold. Meanwhile, the company's second program, lonvo-z, continues to advance, providing a valuation backstop.
Is ARK’s Buying Spree Reshaping Intellia Therapeutics’ (NTLA) Risk‑Reward Story Amid Clinical Uncertainty?
ARK Invest has recently engaged in a three-day buying streak of Intellia Therapeutics (NTLA) stock, despite the company's ATTR program remaining on clinical hold and mixed analyst ratings. This institutional interest, combined with unresolved safety concerns and limited commercial visibility, creates a complex risk-reward profile for the CRISPR-based gene editing company. The article suggests that while ARK's activity highlights a willingness to invest in volatility, it primarily sharpens rather than redefines Intellia's existing investment narrative, which is heavily reliant on regulatory clarity and progress in its lead programs.
Decoding the Gene Editing Sector and Focusing on Progress and Investment Perspectives of Three Leading Companies
The gene editing market, projected to reach $30.8 billion by 2032, holds revolutionary potential for treating genetic diseases. This article highlights three leading companies—Intellia Therapeutics, CRISPR Therapeutics, and Beam Therapeutics—showcasing their progress with clinical trials and regulatory approvals. While the sector offers significant long-term returns, investors face high risks including stock volatility, clinical trial failures, and regulatory hurdles.
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Sharp Rebound And DCF Upside Signals
This article analyzes Intellia Therapeutics (NTLA) post a recent sharp rebound, evaluating its current valuation using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) models. While the DCF model suggests the stock is significantly undervalued by 94.5% at an intrinsic value of $234 per share compared to its current price of $12.83, the P/S ratio indicates it is overvalued relative to industry and peer averages. The article highlights that for rapidly growing biotech companies, P/S can be more informative than P/E, but also introduces the "Narratives" approach for investors to connect their beliefs about a company's prospects with financial forecasts.
Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals
Intellia Therapeutics (NTLA) has experienced a recent share price rebound after a period of decline, showing a 35.4% one-month return. Despite this, the company, currently trading at US$12.50, is still loss-making. Conflicting valuation signals exist, with one narrative suggesting a 43.9% undervaluation with a fair value of US$22.27, while a DCF model indicates it's extremely cheap with a fair value of US$233.98.
A Look At Intellia Therapeutics (NTLA) Valuation After ARK’s Added Stake And J.P. Morgan Conference Spotlight
Intellia Therapeutics (NTLA) is gaining attention after ARK Investment increased its stake and the company prepares for the J.P. Morgan Healthcare Conference. While a narrative model suggests the stock is significantly undervalued with a fair value of $22.27, based on its promising clinical pipeline and favorable market trends, a simple P/S ratio analysis indicates it is expensive compared to its peers. Investors are encouraged to consider both perspectives and associated risks like trial safety and potential dilution.
A Look At Intellia Therapeutics (NTLA) Valuation After ARK’s Added Stake And J.P. Morgan Conference Spotlight
Intellia Therapeutics (NTLA) is drawing renewed interest following ARK Investment's increased stake and its upcoming presentation at the J.P. Morgan Healthcare Conference. While the stock has seen recent gains after a volatile period, Simply Wall St's analysis suggests NTLA is undervalued with a fair value of $22.27, primarily driven by the potential of its clinical pipeline and market expansion. However, a high P/S ratio indicates the stock is expensive, highlighting conflicting valuation signals.
Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak
Cathie Wood's ARK Invest has continued its buying spree of Intellia Therapeutics (NTLA) stock, purchasing 56,769 shares on Thursday, totaling approximately $682,000. This marks the third consecutive day of ARK's accumulation of NTLA shares. Despite a 23% drop in 2025 due to a patient death, Intellia's stock has rebounded over 32% year-to-date in 2026, driven by clinical trial progress and investor confidence, with analysts maintaining a "Moderate Buy" rating.
